CLSDQ (Clearside Biomedical) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLSDQ Clearside Biomedical Inc CLSDQ
44 GF Score
Price $0.25
GF Value $6.16
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Clearside Biomedical Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

CLSDQ
44GF Score
Clearside Biomedical Inc CLSDQ
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Clearside Biomedical (CLSDQ) Overvalued in 2026?

Based on GuruFocus' analysis, Clearside Biomedical stock appears to be undervalued. The current stock price of $0.25 is trading 96% below its estimated GF Value™ of $6.16. GuruFocus considers Clearside Biomedical to be Possible Value Trap.

Key valuation signals for CLSDQ:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: $6.16 vs. price of $0.25 (96% below fair value)
  • GF Score™: 44/100 with 7 warning signs

No single metric tells the full story. See the CLSDQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Clearside Biomedical Business Description

Address 900 North Point Parkway, Suite 200, Alpharetta, GA, USA, 30005
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
44GF Score

Get the complete analysis for CLSDQ

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price
$6.16
GF Value